Will feature drug discovery, gene and RNA therapy technology
Johnson & Johnson has opened its San Francisco Bay campus, a state-of-the-art research & development facility in the Bay Area, often known as global hub for innovation and entrepreneurship. The nearly 200,000 square-foot facility will be home to up to 400 employees, more than doubling the R&D presence of J&J in that area. The campus connects scientific and technological capabilities by co-locating Janssen R&D, Johnson & Johnson Innovation and Johnson & Johnson Technology.
The R&D focus at the new site spans Janssen’s therapeutic areas and key functions, including emerging science and technologies for gene and RNA therapies; novel treatments and approaches for retinal and infectious diseases; and advanced data science, including artificial intelligence and machine learning.
“Our new state-of-the-art science facility in the Bay Area will further strengthen our R&D capabilities and transform how we discover, develop, and deliver innovative medicines faster and more efficiently. By integrating drug discovery, data science, and digital health, we aim to accelerate the growth of our best-in-class portfolio and deliver better health outcomes for people worldwide,” says James Merson, PhD, site head, San Francisco Bay campus and global therapeutic area head, infectious diseases, Janssen Research & Development, LLC.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Boosting Patient Adherence: The Power of Clinical Support Programs
October 3rd 2024In this podcast, we speak with Amanda Scholz, UBC Senior Clinical Program Manager, MHA, BSN, RN as we discuss the important role that clinical adherence programs play in empowering patients and bolster persistence to prescribed life-changing medications throughout their journey.